The fluorescence-activated cell sorter (FACS) was utilized to phenotype lymphocyte compartments in children receiving intensive chemotherapy for acute lymphoblastic leukemia (ALL). Sixteen patients (eight males and eight females) of diverse ages, risks of relapse, and within weeks 7-53 of maintenance/continuation chemotherapy treatment were arbitrarily selected for study. All 16 patients had profound B cell lymphopenia. In contrast, T cell numbers were often normal or marginally low, and accounted for up to 98% of the lymphocyte populations. No abnormality in T cell phenotypes could be demonstrated. Due to the highly skewed B/T lymphocyte ratios in these ALL patients, the absolute white blood cell counts and lymphocyte percentages were not predictive of the underlying B cell lymphopenia. Patients were also tested for serum immunoglobulin levels and most had abnormally low IgG and IgM. None of four patients immunized with the 1996-1997 influenza virus vaccine seroconverted to at least two vaccine antigens as compared to 10 of 10 healthy, age-matched controls. In total, these data highlight for the first time the profound abnormality of the B/T lymphocyte ratio in patients during treatment for ALL, and argue for consideration of B cell-targeted immunotherapy.
Introduction
The survival of children diagnosed with acute lymphoblastic leukemia (ALL) has steadily increased over the past several decades due to advances in modern chemotherapeutic treatment regimens. However, the intensification of combination chemotherapy for purposes of eliminating leukemic cell populations leads to substantial immunosuppression. It is welldocumented that infection is a major complication of cancer therapy, [1] [2] [3] [4] and poor vaccine responses hinder attempts to prevent infection among patients undergoing therapy for ALL. 5, 6 Of note, primary immune responses in these patients are particularly impaired 7 and some reports suggest that such immunosuppression persists for years after cessation of therapy. 8, 9 The immunodeficiencies of ALL patients have been attributed to abnormalities such as altered IL-2 production or loss of cell surface receptor expression by T cell subsets. 10 Other groups have noted deficiencies involving both B and T cells such as decreased absolute lymphocyte counts and hypogammaglobulinemia. [11] [12] [13] [14] However, these groups have not directly compared B cell and T cell compartments in children undergoing modern regimens of chemotherapy. Here we util- ize the fluorescence-activated cell sorter (FACS) to characterize lymphocyte subsets in the ALL patient population.
Materials and methods

Patients and treatments
Sixteen patients ranging in age from 3 to 19 years and receiving treatment for ALL were studied (see Table 1 ). Three patients (Nos 6, 13 and 14) were being treated for T-ALL, while all other patients were being treated for B-ALL. Ten and six patients were diagnosed as having high-risk and low-risk ALL, respectively. All patients were enrolled in the Total Therapy Study XIIIB (see below) and were between weeks 7 and 53 on maintenance/continuation chemotherapy treatment at St Jude Children's Research Hospital (SJCRH).
In the Total XIIIB study, patients are randomized to receive an 'up-front window therapy' of intravenous (i.v.) 6-mercaptopurine (6MP) alone or either high-dose i.v. methotrexate (MTX) or fractionated lower-dose oral MTX followed by 6MP infusion. Approximately 72 h after the start of 6MP therapy, all patients begin a 6-week remission induction/consolidation therapy and receive prednisone, vincristine, daunorubicin, lasparaginase, etoposide and cytarabine, followed by highdose MTX in combination with 6MP. Continuation therapy 
Lymphocyte analyses
During routine patient visits for maintenance therapy (weeks 7-53), complete blood cell counts (CBC) and lymphocyte analyses were performed. For reference values, normal leukocyte and lymphocyte counts and relative percentages are provided in Table 1 . 15, 16 Lymphocyte subpopulations were analyzed by flow cytometry with three-color analyses. Peripheral blood lymphocytes were stained with PerCP (PCP)-labeled anti-CD45 monoclonal antibody and leukocytes were gated by forward and side scatter parameters. The CD45-positive population (leukocytes) was then analyzed for B cells and T cells using phycoerythrin (PE)-labeled anti-CD19 and fluoroisothiocyanate (FITC)-labeled anti-CD3 antibodies, respectively. Phenotypes of T cell populations were obtained by staining lymphocytes with PCP-labeled anti-CD3 antibody plus combinations of FITC and PE-labeled antibodies specific for CD4, CD8, ␣␤ T cell receptor (TCR), ␥␦ TCR, V␤2 TCR, V␤8 TCR, CD45RA, CD45RO, CD69, CD25, and MHC Class II (DR). Cells were stained with appropriate isotype control antibodies and non-specific staining was not observed. Antibodies used for flow cytometry were purchased from Becton Dickinson (San Jose, CA, USA). After staining, cells were processed (Coulter Multi-Q-Prep) and analyzed on a Coulter Epics XL flow cytometer (Coulter, Miami, FL, USA).
Serologic analyses
Measurements of total IgG and IgM were performed on patient serum samples (and compared to manufacturer's reference values (see Table 2 )) with the ARRAY rate nephelometric system (Beckman Instruments, Fullerton, CA, USA). Four patients received the 1996 trivalent inactivated influenza vaccine during this study (standard practice at St Jude Children's Research Hospital) and sera were obtained from these children before and 4 weeks after immunization. Sera were tested for specific antibody with the hemagglutination inhibition (HI) kit (1996-97 CDC Reference Kit, Atlanta, GA, USA). Ten healthy children who received the same vaccine served as controls. A response to the vaccine was scored as positive if antibody levels were increased at least four-fold over pre-vaccination titers and a minimal titer of 1:40 was achieved to at least two vaccine antigens.
Statistical analyses
Statistical analyses were performed using the Wilcoxon rank sum test to compare the distributions of B/T lymphocyte ratios between patient samples (n = 16, nine patients р6 years of age and seven patients Ͼ6 years of age) and healthy controls. Controls were from St Jude Children's Research Hospital (n = 84, 26 controls р6 years of age and 58 controls Ͼ6 years of age). Responses to the influenza vaccine were analyzed with the Fisher's exact test.
Results and discussion
Clinical assays and the flow cytometer were used to enumerate and characterize white blood cell populations from 16 
CD3
+ ) numbers were normal or marginally low in most patients and could account for up to 98% of the total lymphocyte population. Several patients were evaluated repeatedly for months during their course of therapy without substantial changes in their lymphocyte populations. B/T ratios from patient and healthy, age-matched control populations were compared with the Wilcoxon rank sum test, demonstrating statistically significant differences with P Ͻ 0.0001 for both age-defined subgroups (see Materials and methods for details).
Further analyses were performed with seven of the patient samples to measure expression levels of CD4, CD8, ␣␤ T cell receptor (TCR), ␥␦ TCR, V␤2 TCR V␤8 TCR, CD45RA, CD45RO, CD69, CD25 and MHC Class II (DR) in the CD3 + population. In all cases, T cell phenotypes were comparable to those of healthy controls (data not shown). White cell, neutrophil and total lymphocyte numbers were often low, but were not profoundly and consistently deficient, as was the case for the B cell subset.
Results in Table 2 show that the ALL patients had low to below normal levels of serum IgG and markedly low levels of serum IgM. The serologic response to the 1996-1997 influenza vaccine was measured in four of the ALL patients and 10 healthy controls. Ten of the 10 healthy children, and none of the four patients, achieved a positive antibody response to at least two vaccine antigens. Results from patient and control populations were evaluated with the Fisher's exact test, demonstrating a statistically significant difference with P = 0.001. These data suggest that although the influenza virus vaccine is considered safe for administration to ALL patients, the benefit may be minimal.
A review of individual medical records revealed that each ALL patient had experienced at least one infection-related admission (defined by fever, fever and neutropenia, or a documented positive culture) during therapy. Notably, six of 16 children were admitted an average of once a month on this basis.
Our observations support previous findings that pediatric patients undergoing maintenance chemotherapy for ALL have a deficiency of B lymphocyte numbers and function. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, our data further show that T cell numbers are often normal. Thus, we demonstrate for the first time the profoundly low B/T ratios in ALL patients. Our flow cytometric analyses also indicate that T cell populations are phenotypically normal (with regard to activation markers and cell surface receptors). The selective loss of B cells in ALL patients may be caused by disease and/or may be a predictable consequence of cytotoxic therapies that target B cell ALL. 17, 18 Our results suggest that immunotherapies should be designed not merely to enhance immune responsiveness, but to specifically correct or supplement B cell functions in ALL patients.
